Healthcare
Response Genetics, Inc(RGDXQ)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +7.9%
- EPS Growth
- -48.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Response Genetics, Inc (RGDXQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +7.9%, EPS growth of -48.6%, a dividend yield of 0.0%. What stands out right now is revenue +7.9%, EPS -48.6%, free cash flow -2.4% with operating margin -118.5% and ROIC -49.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RGDXQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.9% vs +7.6% peer median
Operating Margin
Below sector median
-118.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2015 was reported on Mar 31, 2015, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.9% and EPS is at -48.6%, with operating margin around -118.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2015 Mar 31, 2015 | โ | +0.0% | +0.0% | +0.0% |
2014 Dec 31, 2014 | โ | +0.0% | +0.0% | +0.0% |
2014 Sep 30, 2014 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGDXQ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RGDXQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RGDXQ and SPY.
Company Overview
Response Genetics, Inc
Other OTC
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
- Leadership
- Thomas Bologna
- IPO Date
- Jun 5, 2007
- Employees
- 96
- Street Address
- 1640 Marengo Street
- Mailing
- Los Angeles, CA, 90033
- Region
- Los Angeles, CA, US
- Reporting Currency
- USD
- Investor Line
- 323-224-3900
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.7
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- +7.9%
- EPS
- -48.6%
- Free Cash Flow
- -2.4%
Profitability
- Gross Margin
- 21.9%
- Operating Margin
- -118.5%
- Net Margin
- -111.9%
- ROE
- -126.8%
- ROIC
- -49.9%
Balance Sheet
- Debt/Equity
- 0.19
- Current Ratio
- 2.86
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.